Department of Internal Medicine, Erasmus Medical Center Rotterdam, Netherlands.
Front Immunol. 2012 Jul 20;3:212. doi: 10.3389/fimmu.2012.00212. eCollection 2012.
The research on T cell immunosuppression therapies has attracted most of the attention in clinical transplantation. However, B cells and humoral immune responses are increasingly acknowledged as crucial mediators of chronic allograft rejection. Indeed, humoral immune responses can lead to renal allograft rejection even in patients whose cell-mediated immune responses are well controlled. On the other hand, newly studied B cell subsets with regulatory effects have been linked to tolerance achievement in transplantation. Better understanding of the regulatory and effector B cell responses may therefore lead to new therapeutic approaches. Mesenchymal stem cells (MSC) are arising as a potent therapeutic tool in transplantation due to their regenerative and immunomodulatory properties. The research on MSCs has mainly focused on their effects on T cells and although data regarding the modulatory effects of MSCs on alloantigen-specific humoral response in humans is scarce, it has been demonstrated that MSCs significantly affect B cell functioning. In the present review we will analyze and discuss the results in this field.
在临床移植中，T 细胞免疫抑制疗法的研究吸引了大部分的关注。然而，B 细胞和体液免疫反应被越来越多地认为是慢性移植物排斥反应的关键介质。事实上，即使细胞介导的免疫反应得到很好的控制，体液免疫反应也会导致肾移植排斥。另一方面，新近研究的具有调节作用的 B 细胞亚群与移植中的耐受形成有关。因此，更好地了解调节性和效应性 B 细胞反应可能会导致新的治疗方法。间充质干细胞（MSC）由于其再生和免疫调节特性，正在成为移植中的一种有效治疗工具。对间充质干细胞的研究主要集中在它们对 T 细胞的作用上，尽管关于间充质干细胞对人类同种抗原特异性体液反应的调节作用的数据很少，但已经证明间充质干细胞显著影响 B 细胞的功能。在本综述中，我们将分析和讨论这一领域的结果。
